|
A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Genenta Science |
Stock and Other Ownership Interests - Genenta Science |
| |
|
Employment - Genenta Science |
Leadership - Genenta Science |
Stock and Other Ownership Interests - Genenta Science |
Honoraria - Genenta Science |
Consulting or Advisory Role - Genenta Science |
Travel, Accommodations, Expenses - Genenta Science |
| |
|
Stock and Other Ownership Interests - Genenta Science |
Consulting or Advisory Role - Genenta Science |
Research Funding - Genenta Science |
Patents, Royalties, Other Intellectual Property - Genenta Science |
| |
|
No Relationships to Disclose |